BR112022008235A2 - Portadores de fármacos poliméricos biocompatíveis para a liberação de agentes ativos - Google Patents

Portadores de fármacos poliméricos biocompatíveis para a liberação de agentes ativos

Info

Publication number
BR112022008235A2
BR112022008235A2 BR112022008235A BR112022008235A BR112022008235A2 BR 112022008235 A2 BR112022008235 A2 BR 112022008235A2 BR 112022008235 A BR112022008235 A BR 112022008235A BR 112022008235 A BR112022008235 A BR 112022008235A BR 112022008235 A2 BR112022008235 A2 BR 112022008235A2
Authority
BR
Brazil
Prior art keywords
release
copolymer
active agents
biocompatible polymeric
polymeric drugs
Prior art date
Application number
BR112022008235A
Other languages
English (en)
Inventor
Geraths Christian
Thommen Christophe
Hackebeil Michael
Panighetti Davide
Hitz Hans
Original Assignee
Cis Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cis Pharma Ag filed Critical Cis Pharma Ag
Publication of BR112022008235A2 publication Critical patent/BR112022008235A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F2/00—Processes of polymerisation
    • C08F2/38—Polymerisation using regulators, e.g. chain terminating agents, e.g. telomerisation
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
    • C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F220/10—Esters
    • C08F220/34—Esters containing nitrogen, e.g. N,N-dimethylaminoethyl (meth)acrylate
    • C08F220/36—Esters containing nitrogen, e.g. N,N-dimethylaminoethyl (meth)acrylate containing oxygen in addition to the carboxy oxygen, e.g. 2-N-morpholinoethyl (meth)acrylate or 2-isocyanatoethyl (meth)acrylate
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
    • C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F220/52—Amides or imides
    • C08F220/54—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
    • C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F220/52—Amides or imides
    • C08F220/54—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide
    • C08F220/58—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide containing oxygen in addition to the carbonamido oxygen, e.g. N-methylolacrylamide, N-(meth)acryloylmorpholine
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F2438/00—Living radical polymerisation
    • C08F2438/03—Use of a di- or tri-thiocarbonylthio compound, e.g. di- or tri-thioester, di- or tri-thiocarbamate, or a xanthate as chain transfer agent, e.g . Reversible Addition Fragmentation chain Transfer [RAFT] or Macromolecular Design via Interchange of Xanthates [MADIX]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Polymers & Plastics (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

PORTADORES DE FÁRMACOS POLIMÉRICOS BIOCOMPATÍVEIS PARA A LIBERAÇÃO DE AGENTES ATIVOS. A presente divulgação refere-se à liberação de múltiplas cópias de uma molécula de carga útil, tal como um agente ativo ou um agente quelante capaz de capturar um agente ativo, usando como portador para sua liberação um copolímero biocompatível compreendendo aminoácidos ligados à cadeia lateral funcionalizados em seu grupo alfa-amino por uma porção de azida reativa por meio da qual as moléculas de carga útil são acopladas ao copolímero. O copolímero é tipicamente ainda funcionalizado para conter uma única cópia de uma porção de alvejamento específica do tipo de célula ou específica do tipo de tecido.
BR112022008235A 2019-10-30 2020-10-30 Portadores de fármacos poliméricos biocompatíveis para a liberação de agentes ativos BR112022008235A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962973844P 2019-10-30 2019-10-30
PCT/EP2020/080545 WO2021084087A1 (en) 2019-10-30 2020-10-30 Biocompatible polymeric drug carriers for delivering active agents

Publications (1)

Publication Number Publication Date
BR112022008235A2 true BR112022008235A2 (pt) 2022-07-12

Family

ID=73059872

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022008235A BR112022008235A2 (pt) 2019-10-30 2020-10-30 Portadores de fármacos poliméricos biocompatíveis para a liberação de agentes ativos

Country Status (10)

Country Link
US (1) US20220409737A1 (pt)
EP (1) EP4051320A1 (pt)
JP (1) JP2023500112A (pt)
KR (1) KR20220092565A (pt)
CN (1) CN114641316A (pt)
AU (1) AU2020376310A1 (pt)
BR (1) BR112022008235A2 (pt)
CA (1) CA3150503A1 (pt)
IL (1) IL291539A (pt)
WO (1) WO2021084087A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023287857A1 (en) * 2021-07-14 2023-01-19 Washington University Systems and methods for low-count quantitative projection domain spect imaging
WO2024100200A1 (en) 2022-11-09 2024-05-16 Cis Pharma Ag Anti-l1-cam antibodies and their uses for diagnostic and therapeutic applications

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
US5508269A (en) 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US6083922A (en) 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
US5767068A (en) 1997-02-13 1998-06-16 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
CZ293787B6 (cs) * 2001-12-20 2004-07-14 Zentiva, A.S. pH senzitivní polymerní konjugáty antracyklinového kancerostatika pro cílenou terapii
EP2777714A1 (en) 2013-03-15 2014-09-17 NBE-Therapeutics LLC Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
EP3356433B1 (en) 2015-10-02 2019-09-18 CIS Pharma AG New polymer materials for contact lens applications

Also Published As

Publication number Publication date
KR20220092565A (ko) 2022-07-01
CA3150503A1 (en) 2021-05-06
AU2020376310A1 (en) 2022-03-24
CN114641316A (zh) 2022-06-17
JP2023500112A (ja) 2023-01-04
IL291539A (en) 2022-05-01
US20220409737A1 (en) 2022-12-29
WO2021084087A1 (en) 2021-05-06
EP4051320A1 (en) 2022-09-07

Similar Documents

Publication Publication Date Title
BR112022008235A2 (pt) Portadores de fármacos poliméricos biocompatíveis para a liberação de agentes ativos
MX2020010687A (es) Composiciones de oligonucleotidos y metodos de uso de las mismas.
CL2020003260A1 (es) Compuestos de naftiridinona sustituidos útiles como activadores de células t
WO2018191502A3 (en) Anti-cd137 antibodies and methods of use thereof
BR112014005543A2 (pt) sistema de descarte de medicação geral
MX2020012679A (es) Compuestos de amino-pirazincarboxamida, conjugados, y usos de los mismos.
CL2009000815A1 (es) Compuestos derivados de fenilhidroximetilpirrolidina, agonista del recptor adrenergico beta 3; composicion farmaceutica que los comprende; uso en el tratamiento de vejiga hiperactiva, incontinencia urinaria por impulso y urgencia urinaria.
AR081993A1 (es) TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON LA SUBUNIDAD a REGULADA POR VOLTAJE DEL CANAL DE SODIO (SCNA) POR INHIBICION DEL TRANSCRIPTO ANTISENTIDO NATURAL DE SCNA
AR090316A1 (es) Cepa de flavobacterium plaguicida y composiciones bioactivas, metabolitos y usos
BR112012008142A8 (pt) conjugados de peptídeo/ polietilenoglicol ligados a dissulfeto para a transfecção de ácidos nucleicos
BR112019007927A2 (pt) conjugados de polimixina ? oligômeros de alginato
PH12021500011A1 (en) Anti-cd137 antigen-binding molecule and utilization thereof
BR112018072198A2 (pt) composição compreendendo micrornas, método de preparação de uma composição de célula-tronco restaurada, formulação farmacêutica e kit
CL2018003044A1 (es) 6-aminopiridina-3-yl tiazoles como moduladores de ror.
MX2022009819A (es) Moleculas de union al antigeno anti-grupo de diferenciacion 137 (cd137) para usarse en el tratamiento contra el cancer.
BR112019003136A2 (pt) forma de dosagem multiunitária de composição farmacêutica, forma de dosagem unitária de composição farmacêutica, forma de dosagem multiunitária / unitária, kit e método de tratamento de uma condição tratável por administração oral de um agente terapeuticamente ativo
BR112022026397A2 (pt) Métodos para tratar câncer usando derivados de amida de heteroaril-bifenila
BR112022008183A2 (pt) Formas de sal de um receptor de c5a de componente do complemento
BR112012033773A2 (pt) composição de formulação agroquímica,e, método para usar uma composição de formulação agroquímica.
CL2020001358A1 (es) Cepa vacunal de brucella modificada para el tratamiento de brucelosis
BR112022004032A2 (pt) Composições probióticas mixotróficas e usos das mesmas no tratamento de distensão abdominal
AR066373A1 (es) Formulaciones de aminoacidos n-halogenados
BR112013026909A2 (pt) Produtos medicinais para uso em condições correlacionadas a infecções microbianas no trato aerodigestivo superior
BR112019008698A2 (pt) método para tratar câncer num sujeito que precisa do mesmo e composição farmacêutica
WO2019216744A3 (ko) 클릭화학 반응을 통해 필러 또는 약물전달체로 사용하기 위한 주사제형 조성물